HLA-A*0201 & B2M & PRAME (SLLQHLIGL)

HLA-A*0201 & B2M & PRAME (SLLQHLIGL) Product List

  • Product Category

    Protein (1)

  • Product Status

    Launched (1)

  • Species

    Human (1)

  • Tag

    His Tag & Avi Tag (1)

  • Conjugate

    Biotin-labeled (1)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
HLE-H82E8
Human
HEK293
Biotinylated Human HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Complex Protein (Monomer, MALS verified)
Total: 1
  • 1

HLA-A*0201 & B2M & PRAME (SLLQHLIGL) Background

This gene encodes an antigen that is preferentially expressed in human melanomas and that is recognized by cytolytic T lymphocytes. It is not expressed in normal tissues, except testis. The encoded protein acts as a repressor of retinoic acid receptor, and likely confers a growth advantage to cancer cells via this function. Alternative splicing results in multiple transcript variants. The PRAME (SLLQHLIGL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 PRAME (SLLQHLIGL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M and PRAME (SLLQHLIGL) peptide.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
NM26-2198NM-26-2198Phase 1 ClinicalKaken Pharmaceutical Co Ltd, Numab Therapeutics AgInflammation; Dermatitis, Atopic
Details
  • Product List
  • Clinical Drug Information